Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model

About this update from Creative Medical Technology Holdings, Inc.

[{"type":"text","content":"Commercial Stage Stem Cell Company Achieves Selective Reprogramming of Pathological Autoimmunity\n\n\nPHOENIX, Sept. 29, 2020 /PRNewswire/ -- (OTC-CELZ) -- Creative Medical Technology Holdings announced today proof of concept studies demonstrating efficacy of its ImmCelz® immunotherapy product in the collage induced model of rheumatoid arthritis. The studies, which involved exposing mouse immune cells to the Company's patent pending \"ex vivo\" reprogramming protocol, demonstrated selective suppression of autoimmunity which causes joint damage, while sparing of normal immune functions. Current treatments for rheumatoid arthritis non-specifically depress immune responses leading to increased susceptibility to infections.\n\n \n \n \n \n \n \n\n \n\"Previous publications have demonstrated ability to selectively suppress harmful immune responses using complicated gene modification technology1,\" said Timothy Warbington, CEO. \"The data disclosed suggest ability of ImmCelz® to achieve superior results in a manner which is amenable to rapid clinical translation.\"\nImmCelz®, which is protected by trade secrets and published US patent application 15/987739, utilizes adult stem cells derived from qualified donors, to endow specific properties to patient immune cells. After the patient immune cells are incubated with the donor stem cells, the immune cells are extracted and re-injected back into the patient. These \"reprogrammed cells\" subsequent \"educate\" other cells of the immune system to stop attacking the body, while preserving ability to attack cancers and foreign pathogens.\n\"Immunotherapy represents a revolution in medicine in which cells of the immune system are being developed as drugs.\" \"While majority of efforts are focused on stimulation of immunity, for treatment of cancer and viruses, our ImmCelz® product represents a radically novel platform aimed at selective suppression of harmful immune response,\" Timothy Warbington further said.\nHarmful immune responses, otherwise known as autoimmunity, are a multibillion dollar market which comprises conditions such as type 1 diabetes, multiple sclerosis, lupus, rheumatoid arthritis, and Grave's Disease.\n\"As the company continues to progress with commercialization of our patented and clinically tried CaverStem® technology for the treatment of erectile dysfunction, our FemCe...

More updates from Creative Medical Technology Holdings, Inc.